Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 15, 2013. The report details a specific share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure and share buyback activity.
- Shares Purchased: 330,000 Ordinary Shares of 25 pence each.
- Purchase Date: March 15, 2013.
- Price Range: Highest price paid was 1,497 pence per share; lowest price paid was 1,490.5 pence per share.
- Treasury Holdings (Settled): 496,431,327 shares (9.19% of total issued share capital).
- Treasury Holdings (Including Unsettled): 497,291,327 shares (10.13% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,907,831,550 shares.
Material Changes
The filing reports a reduction in outstanding shares due to the repurchase of 330,000 shares. Consequently, the percentage of shares held in Treasury increased to 10.13% of total voting rights when including unsettled purchases. No other material changes to operations or financial position are disclosed in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a routine disclosure of a share buyback transaction and does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (496,431,327 settled) against the company's latest annual report.
- Confirm the total issued share capital excluding treasury shares (4,907,831,550) for voting rights calculations.
- Check the settlement status of the 860,000 shares included in the "including unsettled" figure to determine the final treasury percentage.
- Review the authority granted at the May 3, 2012 AGM to ensure the repurchase was within the approved limit.